SCHEDULE: Logos Global Management Discloses Yarrow Bioscience Stake

Logos Global Management LP and affiliated entities have reported beneficial ownership of 9.9% of Yarrow Bioscience, Inc. common stock, including shares and pre-funded warrants.

Summary

• Logos Global Management LP, along with several affiliated entities, has filed a Schedule 13G, indicating their beneficial ownership of Yarrow Bioscience, Inc. common stock.
• The total beneficial ownership reported is 9.9% of the outstanding shares.
• This ownership includes both directly held shares of common stock and pre-funded warrants.
• The filing specifies that the ownership is subject to a 9.99% beneficial ownership limitation.
• The percentage of class represented by the amount beneficially owned is 9.9% for all reporting persons.
• The outstanding shares of common stock as of July 29, 2026, were reported as 2,669,788.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports on beneficial ownership changes and does not contain operational or financial performance data.

Positives

• The filing clearly outlines the beneficial ownership stake held by Logos Global Management and its affiliates.
• The reporting is conducted in compliance with SEC regulations, providing transparency to the market.

Negatives

• The filing does not provide any information on the company's financial performance, operational status, or future business prospects.
• The nature of the pre-funded warrants and their potential impact on future dilution is not detailed beyond the ownership percentage.

Risks

• The beneficial ownership is subject to a 9.99% limitation, suggesting potential adjustments or future filings if this threshold is approached or exceeded.
• The filing does not provide insight into the investment strategy or rationale behind acquiring this stake, leaving potential future actions open to speculation.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Yarrow Bioscience, Inc.'s future performance.

Management Comments

• Each reporting person disclaims beneficial ownership of Common Stock except to the extent of that person's pecuniary interest therein.
• The filing of this Schedule 13G on behalf of the Global Fund or Opp Fund V should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any Common Stock covered by this Schedule 13G.
• The shares reported herein consist of [number] shares of Common Stock and prefunded warrants to acquire [number] shares of Common Stock, subject to a 9.99% beneficial ownership limitation.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in public companies. This filing indicates a notable position taken by Logos Global Management in Yarrow Bioscience, Inc., which may signal strategic interest or a passive investment approach.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant beneficial ownership, which could influence market perception and trading activity.
• Management of Yarrow Bioscience, Inc.: Awareness of a substantial stake held by Logos Global Management, potentially impacting strategic discussions or future corporate actions.

Next Steps

• Logos Global Management and affiliated entities will continue to monitor their beneficial ownership levels in Yarrow Bioscience, Inc.
• Further filings may be required if ownership levels change significantly or approach the 9.99% beneficial ownership limitation.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Logos Global Management, Yarrow Bioscience, Prefunded Warrants, Investment Holding